Metropolis Healthcare Q2 Results: Profit Jumps 31%, Meets Estimates
Metropolis Healthcare's Ebitda margin expanded to 25.7% in the September quarter from 24.2% in the year-ago period.
Metropolis Healthcare Ltd.'s consolidated net profit rose 31% in the second quarter of fiscal 2025, meeting analysts' estimates.
The diagnostic service provider's profit stood at Rs 46.7 crore in the quarter ended September, compared with Rs 35.7 crore in the same period of the previous fiscal, according to an exchange filing on Friday. The consensus estimate of analysts tracked by Bloomberg stood at Rs 47 crore.
Revenue from operations during the quarter stood at Rs 350 crore, marking a year-on-year growth of 13%. This was driven by sustained growth in patient volumes and test volumes, at 7% and 8%, respectively. The revenue per patient increased by 6%.
Metropolis Q2 FY25 Highlights (Consolidated, YoY)
Revenue up 13% to Rs 350 crore (Bloomberg estimate: Rs 350 crore).
Ebitda up 32% to Rs 89.9 crore (Estimate: Rs 90 crore).
Ebitda margin expands to 25.7% from 24.2% (Estimate: 25.8%).
Net profit up 31% to Rs 46.7 crore (Bloomberg estimate: Rs 47 crore).
ALSO READ
Q2 Results: Fortis Healthcare Profit Miss Estimates; Premiere Energies Profit Grows Three-Fold
The company's business-to-consumer revenue growth, at 21%, outpaced overall performance in the July-September period, fuelled by same store growth of 12%, and addition of over 400 new centres. The B2C segment accounts for 56% of the overall revenue.
The business-to-business revenue grew by 13% year-on-year during the quarter. The segment contributes to 35% of the overall revenue.
The revenue from 'TruHealth' segment increased by 23% compared to the year-ago period, according to Metropolis Healthcare.
Commenting on the second quarter results, Metropolis Healthcare Chief Executive Officer Surendran Chemmenkotil said the "strong performance has been fuelled by a 21% YoY growth in B2C revenue, along with expansion in Tier 3 cities and an improvement in our average revenue per patient."
"Key growth areas, including our Specialty and TruHealth segments, have also contributed significantly. As we continue to broaden our footprint through our extensive network and valued partnerships, this strategic approach strengthens our position in a competitive landscape and paves the way for sustainable, long-term growth,” he added.
Shares of Metropolis Healthcare closed 0.17% higher at Rs 2,115.45 apiece on the NSE, compared to a 0.21% fall in the benchmark Nifty 50.
